Deed of Variation

RNS Number : 7104V
EKF Diagnostics Holdings PLC
05 November 2010
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Deed of Variation relating to the Acquisition of Quotient Diagnostics Limited

 

EKF Diagnostics Holdings plc (AIM: EKF), which has recently refocused on the in-vitro diagnostic devices market, announces it has entered into a deed of variation to amend the sale and purchase agreement ("SPA") relating to the acquisition, announced on 1 October 2010, of the entire issued share capital of Quotient Diagnostics Limited ("Quotient").

 

Under the terms of the deed of variation, the initial consideration has been increased from £3.41 million to £3.51 million, such increase to be satisfied by the issue of a further 472,613 new ordinary shares ("New Ordinary Shares") at a price of 22p per share, and the maximum deferred consideration payable has been reduced from £2.0 million to £1.9 million. Therefore the maximum total consideration payable for the acquisition of Quotient remains £5.41 million.

 

The variation to the SPA is the result of an amendment to the number of ordinary shares in the Company that were originally issued to the vendors of Quotient on 4 October 2010 and specifically relates to the conversion of certain loan notes that Quotient had issued earlier this year.

 

Application has been made for the New Ordinary Shares to be admitted to AIM and dealings are expected to commence on 10 November 2010.

 

 

Enquiries:

 

EKF Diagnostics Holdings plc

Julian Baines, CEO

Paul Foulger, FD

 

Mob: 07788 420 859

Tel: 020 7823 1733

 

Zeus Capital - Nominated  Adviser and Joint Broker

Ross Andrews

Tom Rowley

 

Tel: 0161 831 1512

Matrix Corporate Capital LLP - Joint Broker

Tel: 020 3206 7000

Robert Naylor

Stephen Waterman

 


Walbrook PR

Paul McManus

 

Tel: 020 7933 8780

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMMGMZKMGGZM
UK 100

Latest directors dealings